Tuesday

Trial Tuesday: China's ASCO Moment

For the first time in ASCO's history, China-only data occupies the plenary slot. A hazard ratio of 0.40 in pancreatic cancer. And Lilly moving the obesity ceiling above bariatric surgery. Chicago has a lot to answer for this week.

Trial

Trial Tuesday: The data almost cooperated. Almost.

Here is a thought experiment: where would we be if the FDA and other regulators did not allow trial flexibility? Keytruda, still the world's best-selling drug, got its initial US approval on a surrogate endpoint. Without that flexibility, it reaches the market at least a year later, and